Abstract
Multimorbidity has been increasing globally and is usually associated with higher health care utilization and costs. Indonesia has been implementing Universal Health Coverage (UHC) program since 2014. However, there is a limited study of the prevalence of multimorbidity and its impact on health care utilization and costs through the UHC scheme in Indonesia. This study aimed to determine the prevalence of multimorbidity and its associated factors, particularly the health care utilization and costs of patients with multimorbidity compared to patients with one chronic condition in the hospitals in Indonesia based on the UHC scheme. The study was a comparative cross-sectional design. The data was collected from the Social Security Agency for Health/Badan Penyelanggara Jaminan Sosial Kesehatan (BPJS Health) National Sample Data 2015-2016. All patients ≥60 years of age and have at least one chronic condition in the hospital were included. Descriptive statistics, bivariate analysis, and multivariable regression analysis were conducted to analyze the data. In a sample of 23,460 patients, the prevalence of multimorbidity was 44.4% among patients with chronic conditions in the hospital. We observed significant difference in gender, marital status, and membership segmentations between patients with multimorbidity and one chronic condition (p<0.05). Health care utilization and costs were significantly higher in multimorbid patients (p<0.001). This positive association between multimorbidity and health care utilization (OR: 1.70, 95% CI: 1.61-1.79) and health care costs (unstandardized coefficient 0.483, 95% CI: 0.443-0.524, p<0.001) remains significant after adjusting for age and gender. The analysis found that the prevalence of multimorbidity was high and positively associated with higher health care utilization and costs through the UHC scheme in Indonesia. Therefore, health policymakers and healthcare professionals need to consider the burden of multimorbidity more when structuring health care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of secondary and sample data, which anonymized by the BPJS Health ensured that the data are no longer traceable back to participants. No ethical permit or informed consent needed in the study due to secondary data use.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available from BPJS Health (https://data.bpjs-kesehatan.go.id/). To gain access to BPJS Health sample data, the researchers need to submit an application to the BPJS Health Information and Documentation Management Officer. This is to ensure the data are properly monitored and in accordance to data governance-based policy.
